Loading...
Relatively modest weight loss in obese adults may improve glucose tolerance and decrease the likelihood for developing diabetes mellitus. In this manufacturer-supported analysis, researchers pooled data from 3 double-blind, placebo-controlled trials of the weight-loss drug orlistat; the studies were conducted in 39 U.S. and European research centers and involved 675 adults (mean age, 44; mean BMI, 36; 83 percent female). Participants ate low-calorie diets during a 4-week run-in period; they were randomized to orlistat (120 mg 3 times daily) or placebo and were followed for a mean of 582 days. The primary outcome assessment was a standard 3-hour glucose tolerance test on day 1 and at the end of treatment.
Mean weight loss was 6.72 kg in the t…